The IMA Group will be partnering with SUNY Schenectady to bring the latest testing technology and methodologies to battle COVID-19.

The IMA Group will be partnering with SUNY Schenectady to bring the latest testing technology and methodologies to battle COVID-19. The individual saliva swab diagnostic test, developed by SUNY Upstate Medical University and Quadrant Biosciences, recently received emergency approval by the FDA. The new test, will be used with Upstate Medical’s and Quadrant’s innovative pool testing, which allows for 10 to 25 people to be screened in one COVID-19 test.

Most importantly, this rapid, affordable and high quality testing from The IMA Group will allow businesses to open more safely as it provides a surveillance tool for both students and the community.  The test can now be scaled across New York State as well as used nationwide. For more information about innovative COVID testing solutions from The IMA Group, email us at contact@theIMAgroup.com.

Read the press release from Governor Cuomo.